Key Points
- Insider buying: Hyunsu Jung bought 7,000 shares of Hyperion DeFi at an average price of $3.70, and then purchased another 1,000 shares the next day at $3.66. After the trades, Jung held 1,384,676 shares, a 0.51% increase in ownership.
- Stock and financial snapshot: Hyperion DeFi opened at $3.70, has a market cap of about $56.09 million, and is trading near its 50-day and 200-day moving averages of roughly $3.65 and $3.66. The stock has ranged from a 52-week low of $1.71 to a high of $17.18.
- Analyst and performance context: The company recently reported a quarterly loss of $7.76 per share on just $0.50 million in revenue, while analysts currently rate the stock a consensus Hold with a $5.88 price target. Recent opinions have been mixed, with both buy and sell ratings from different firms.
Hyperion DeFi, Inc. (NASDAQ:HYPD - Get Free Report) insider Hyunsu Jung purchased 7,000 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was bought at an average cost of $3.70 per share, with a total value of $25,900.00. Following the acquisition, the insider owned 1,384,676 shares of the company's stock, valued at $5,123,301.20. This represents a 0.51% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website.
Hyunsu Jung also recently made the following trade(s):
- On Tuesday, June 2nd, Hyunsu Jung purchased 1,000 shares of Hyperion DeFi stock. The stock was bought at an average cost of $3.66 per share, with a total value of $3,660.00.
Hyperion DeFi Stock Performance
Shares of Hyperion DeFi stock opened at $3.70 on Wednesday. The company has a debt-to-equity ratio of 0.12, a current ratio of 1.97 and a quick ratio of 1.97. The firm has a market cap of $56.09 million, a P/E ratio of -0.37 and a beta of 2.47. The firm has a 50 day simple moving average of $3.65 and a 200 day simple moving average of $3.66. Hyperion DeFi, Inc. has a fifty-two week low of $1.71 and a fifty-two week high of $17.18.
Hyperion DeFi (NASDAQ:HYPD - Get Free Report) last issued its quarterly earnings results on Thursday, March 26th. The company reported ($7.76) earnings per share for the quarter. The company had revenue of $0.50 million for the quarter. Sell-side analysts predict that Hyperion DeFi, Inc. will post 1.78 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of equities analysts have issued reports on the stock. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Hyperion DeFi in a research note on Wednesday, May 20th. Cantor Fitzgerald raised shares of Hyperion DeFi to a "strong-buy" rating in a research note on Thursday, April 9th. Finally, Zacks Research cut shares of Hyperion DeFi from a "hold" rating to a "strong sell" rating in a research note on Monday, March 30th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and two have issued a Sell rating to the company's stock. According to MarketBeat.com, Hyperion DeFi presently has an average rating of "Hold" and a consensus price target of $5.88.
Check Out Our Latest Research Report on Hyperion DeFi
Hedge Funds Weigh In On Hyperion DeFi
Hedge funds and other institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC bought a new position in Hyperion DeFi in the fourth quarter valued at approximately $663,000. Jane Street Group LLC bought a new position in shares of Hyperion DeFi during the fourth quarter worth $493,000. Focus Partners Advisor Solutions LLC bought a new position in shares of Hyperion DeFi during the fourth quarter worth $221,000. Geode Capital Management LLC bought a new position in shares of Hyperion DeFi during the fourth quarter worth $214,000. Finally, State Street Corp bought a new position in shares of Hyperion DeFi during the fourth quarter worth $92,000. 25.84% of the stock is owned by institutional investors.
Hyperion DeFi Company Profile
(
Get Free Report)
Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
